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Items for this week’s EPI Update include: 
  
•        Investigation of pediatric deaths 
•        Influenza update 
•        Revised directions for using rabies immune globulin (human) 
•        Measles – the risk is still present 
• Meeting announcements and training opportunities  
  
Investigation of pediatric deaths 
The Iowa Department of Public Health is investigating a cluster of approximately 
20 pediatric deaths which have occurred in counties across the state of Iowa 
between December 2007 and today. The deaths have occurred in children less 
than four years of age.  
  
Most children had mild to severe respiratory symptoms prior to death. Multiple 
viruses have been isolated in laboratory tests including influenza A and B, 
respiratory syncytial viruses (RSV), and adenoviruses. At this time it is unknown 
whether these viral infections were the principal cause of death. This number of 
deaths is higher than the expected number of deaths for this time of year.  
  
IDPH, including the Center for Acute Disease Epidemiology (CADE) and the 
State Medical Examiner’s Office, is collaborating with other states and the 
Centers for Disease Control and Prevention, and University Hygienic Laboratory 
in this investigation.Health care providers are encouraged to contact CADE at 1-
800-362-2736 with information about: 
  
• cases similar to those in the cluster  
• cases of severe pediatric illness with respiratory symptoms of unknown 
etiology  
• cases of viral infection, including influenza, with rare or unusual 
complications, such as acute necrotizing encephalitis and hepatitis  
  
We are asking the parents of young children to: 
  
1)     Keep children away from people with respiratory diseases/symptoms 
2)     Keep children home from child care or school when ill 
3)     Vaccinate all children with flu vaccine 
4)     Wash hands before carrying or playing with young children 
5)     Avoid situations where large numbers of people gather, because some 
may be ill 
  
  
Influenza update 
Iowa is seeing slightly higher numbers of lab-confirmed influenza cases in the 
age group of 25-  to 64-year-olds. Both young children and those over 64 
account for the highest numbers of hospitalizations attributed to influenza for this 
reporting week. The percentage of physician visits due to influenza-like-illness 
remains high. Nationally, widespread activity was reported by 49 states. For 
more information, visit www.idph.state.ia.us/adper/iisn. 
  
Revised directions for using rabies immune globulin (human) 
The Centers for Disease Control and Prevention (CDC) and the Food and Drug 
Administration (FDA) have been notified by Talecris Biotherapeutics, Inc. that its 
Rabies Immune Globulin (Human), HyperRAB S/D in fixed needle 2 mL pre-filled 
syringe does not address all dosing situations.  Specifically, the fixed needle (22 
gauge, 1.25 inch) and the absence of graduations on the 2 mL pre-filled syringe 
do not permit administration of the recommended dose of Rabies Immune 
Globulin (Human), HyperRAB S/D in one or more of the following situations: 
  
o A dose < 2 mL is required (e.g. for pediatric use);  
o A dose < 2 mL must be injected over multiple sites; or  
o An alternate needle (different length or gauge) is required based on 
the patient (adult or child), wound or site of injection.  
  
Three lots of HyperRAB™ S/D have been manufactured with the 2 mL pre-filled 
syringe configuration (see Table below):   
  
Lot Number      Expiration Date Size/Container  NDC Number      
26N87R1 Jan-26-2009     2 mL pre-filled syringe 13533-618-03    
26N88K1 Jan-26-2009     2 mL pre-filled syringe 13533-618-03    
26N9HP1 Feb-18-2010     2 mL pre-filled syringe 13533-618-03    
  
Health care providers may continue to administer HyperRAB™ S/D supplied in 
the 2 mL pre-filled syringe by following the “Revised Directions for Use” that are 
packaged with these lots.  The full “Revised Directions for Use” of these lots is 
available on-line at 
 www.talecris.com/us/documents/FINAL_FDA_Approved_Revised_Directions_for
_Syringe_Use__21-FEB-08.pdf . Talecris has discontinued manufacturing the 
HyperRAB S/D fixed needle, 2 mL pre-filled syringe.   
  
For additional information regarding this product, please contact Talecris 919-
412-1030, or toll free at 1-800-520-2807. 
  
Human rabies PEP (post-exposure prophylaxis) is recommended when 
potentially infectious material (e.g., saliva) from a rabid animal is introduced via a 
bite, or comes into direct contact with broken skin or mucous membranes.  More 
detailed information regarding evaluation for and administration of PEP is 
available at www.cdc.gov/mmwr/preview/mmwrhtml/00056176.htm. For more 
information about rabies and its prevention, visit 
www.idph.state.ia.us/adper/rabies or CDC at 1-800-CDC-INFO or visit 
www.cdc.gov/rabies. 
  
Measles – the risk is still present. 
Several outbreaks of measles have recently been reported in the U.S. In the last 
two months, in San Diego, California, 11 cases of measles have occurred in 
unvaccinated children who were exposed to a child who had recently traveled to 
Europe with his family. Switzerland has had an ongoing outbreak for the last 15 
months. The possibility of importation of measles into Iowa is higher than usual. 
  
Health care providers should remember to consider measles in ill persons who 
have traveled overseas or to areas having outbreaks of measles. If measles is 
suspected, use appropriate infection control strategies to prevent transmission in 
the health care setting. Meanwhile, maintain high coverage with measles, mumps 
and rubella (MMR) vaccine among children and health care workers.  
  
Visit www.cdc.gov/ncidod/dhqp/gl_isolation for infection control guidelines. Visit 
immunize.org/catg.d/p2010 for the Summary of Recommendations for Childhood 
and Adolescent Immunization and immunize.org/catg.d/p2011 for the Summary 
of Recommendations for Adult Immunization. 
  
Meeting announcements and training opportunities 
  
Save the date 
The 2008 Iowa Public Health Conference will be held April 1 and 2, in Ames at 
the Scheman Conference Center in Ames, Iowa. To download the conference 
brochure or to register online, click on 
www.iowapha.org/DocumentHandler.ashx?DocId=5737  .  
  
Have a healthy and happy week! Spring will come someday. 
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